Evaluating Obinutuzumab Versus Prednisolone for Adults with New Onset Minimal Change Disease in a Randomized Phase IIa Trial

What this Trial Is About

Researchers are studying whether obinutuzumab can effectively treat minimal change disease MCD in adults. The trial compares obinutuzumab with glucocorticoids to see if obinutuzumab is not worse at inducing remission and whether it provides better relapse-free survival after one year. Safety and medical issues during obinutuzumab treatment are also being closely monitored. Participants will receive two doses of obinutuzumab or a standard course of prednisolone, a glucocorticoid, with planned tapering over six months. The study follows a parallel design with random assignment to either treatment, aiming to compare remission rates at 8 weeks and relapse prevention over 52 weeks. During the 52-week study period, participants will attend eight clinic visits and additional visits if relapses occur. Researchers will assess remission status, monitor for relapses, and observe any side effects or medical problems linked to the treatments. This comprehensive follow-up helps understand treatment effectiveness and safety over time.

A Trial to Assess the Efficacy and Safety of Obinutuzumab in Treating Adults With Minimal Change Disease (MCD)